SITC 2017 Abstract Titles – Biomarkers and Immune Monitoring

#

Title

Authors

Affiliations

Keywords

P1

Characterization of the tumor microenvironment and immune profile in non-small cell lung cancer

Hanny Musa¹, Johannes Zimmermann², Felix Segerer², Moritz Widmaier², Mindaugas Andrulis³, Andreas Ackermann¹

¹Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany ²Definiens AG, 80636 Munich, Germany ³Klinikum Ludwigshafen, 67063 Ludwigshafen am Rhein, Germany

Biomarkers | Immune contexture | Gene expression | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Tumor stroma | Immune suppression | Immune monitoring | Inflammation | Checkpoint blockade

P2

ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer antigen-specific T cell responses in patients with metastatic castration-resistant prostate cancer

Sandra M. Hayes1 Robert G. Petit¹, Lawrence Fong², Mark Stein³, Ronald Tutrone⁴, Anthony Mega⁵, Naomi Haas⁶

¹Advaxis Immunotherapies, Inc, Princeton, NJ, USA ²UCSF University of California, San Francisco, CA, USA ³The Cancer Institute of New Jersey CINJ Rutgers, Inc, New Brunswick, NJ, USA ⁴Chesapeake Urology Research Associates, Towson, MD, USA ⁵Lifespan Oncology Clinical Research, Providence, RI, USA ⁶University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA

Tumor antigens | Biomarkers | Immune monitoring | T cell | Vaccine

P3

Persistence of 6-thioguanine-resistant T-cell clones in a melanoma patient with durable antitumor response following treatment with immune checkpoint blockade.

Cindy Zuleger¹, Michael Newton¹, Irene Ong¹, Mark Albertini^1,2

¹Carbone Cancer Center at the University of Wisconsin School of Medicine and Public Health, Madison, WI, USA ²William S. Middleton Memorial Veterans Hospital, Madison, WI, USA

Biomarkers | Checkpoint blockade | Immune monitoring | Solid tumors | T cell

P4

The prognostic and predictive roles of a CD8/PD-L1 signature in cancer

Sonja Althammer¹, Keith Steele², Moritz Widmaier¹, Charles Brown², Tze Heng Tan¹, Lorenz Rognoni¹, Hélène Kaplon³, David Friedrich¹, Brandon W Higgs², Günter Schmidt¹, Koustubh Ranade², Marie-Caroline Dieu-Nosjean³

¹Definiens, Munich, Germany ²Medimmune, Gaithersburg, MD, USA ³INSERM, UMRS 1138, Paris, France

Checkpoint blockade | Biomarkers | Bioinformatics | Tumor microenvironment | Antibody | Clinical trial | Clinical study | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Chemotherapy

P5

Analytical Comparison of Methods Used to Assess Mismatch Repair Deficiency

Steven Anderson¹, Li Cai², Lori Johnson³, Bryan McCune²

¹Covance, Durham, NC, USA ²Integrated Oncology, Research Triangle Park, NC, USA ³Covance, Morrisville, NC, USA

Biomarkers | Checkpoint blockade | Solid tumors

P6

Characterization of AB928, a Dual Adenosine A2aR/A2bR Antagonist That Retains Potency under Conditions of High Albumin and High Receptor Activation

Devika Ashok¹, Lisa Seitz¹, Joanne Tan¹, Adam Park¹, Tim Park¹, Ferdie Soriano¹, Terry Rosen¹, Ehesan Sharif¹, Dillon Miles¹, Manmohan Leleti¹, Juan Jaen¹, Jay Powers¹, Matthew Walters¹, Steve Young¹

¹Arcus Biosciences, Hayward, CA, USA

Myeloid cells | Biomarkers | T cell | Tumor microenvironment

P7

Withdrawn

P8

T cell response profiling in colorectal carcinoma patients reveals an enrichment in responses to specific tumor-associated antigens

Kyle Ferber¹, Johanna Kaufmann¹, Christine McCoy¹, Judy Jacques¹, Abdulmohammad Pezeshki², Ning Wu¹, Michael O'Keefe¹, Crystal Cabral¹, Yana Ostrovsky¹, Jason Dobson¹, Theresa Zhang¹, Pamela Carroll¹, Khashayarsha Khazaie², Jessica Flechtner¹, Wendy Broom¹

¹Genocea Biosciences, Cambridge, MA, USA ²Mayo Clinic, Rochester, MN, USA

Biomarkers | Immune monitoring | Tumor antigens | T cell | Dendritic cell

P9

Using iPair-TCR™ and iPair-TCR+™ to track tumor infiltrating lymphocytes from peripheral blood in a longitudinal breast cancer patient study

Miranda Byrne-Steele¹, Wenjing Pan¹, Xiaohong Hou¹, Brittany Brown¹, Mary Eisenhower¹, Alexa Fort¹, Jian Han¹

¹iRepertoire Inc., Huntsville, AL, USA

Immune monitoring | T cell | Solid tumors | Gene expression | Tumor infiltrating lymphocytes (TILs) | CAR T cells

P10

Epithelial-mesenchymal transition (EMT) signature was inversely associated with activated CD8 infiltration in non-small cell lung cancer (NSCLC)

Young Kwang Chae¹, Sangmin Chang¹, Taeyeong Ko¹, Jonathan Anker¹, Sarita Agte², Wade Iams¹, Marcelo Cruz¹

¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA ²Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

Immune suppression | Immunoscore | T cell | Tumor microenvironment | Biomarkers | Tumor infiltrating lymphocytes (TILs)

P11

WNT/β-catenin pathway is inversely correlated with activated CD8 T cell infiltration in non-small cell lung cancer(NSCLC).

Young Kwang Chae¹, Taeyeong Ko¹, Sangmin Chang¹, Jonathan Anker¹, Sarita Agte², Wade Iams¹, Marcelo Cruz¹

¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA ²Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

Tumor microenvironment | Biomarkers | Immune suppression | Immunoscore | T cell | Tumor infiltrating lymphocytes (TILs)

P12

Precision Immune Monitoring: New 30-parameter Flow Cytometry Uniquely and Comprehensively Defines Immune Checkpoint Expression and T Cell Phenotypes in Tumor Tissue

Pratip Chattopadhyay¹, Amber Giles², Leonard Nettey³

¹NYU Medical School, New York, NY, USA ²NIH, Bethesda, MD, USA ³VRC, NIH, Bethesda, MD, USA

Tumor microenvironment | Immune monitoring | Checkpoint blockade | Biomarkers | T cell | Tumor infiltrating lymphocytes (TILs)

P13

Pre-existing T-cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC)

Sanjeev Mariathasan¹, Shannon J. Turley¹, Dorothee Nickles¹, Yulei Wang¹, Edward E. Kadel III¹, Hartmut Koeppen¹, Kobe Yuen¹, Allessandra Castiglioni¹, Jillian L. Astarita¹, Rafael Cubas¹, Suchit Jhunjhunwala¹, Romain Banchereau¹, Yagai Yang¹, Yinghui Guan¹, Cecile Chalouni¹, James Ziai¹, Yasin Şenbabaoğlu¹, Steve Lianoglou¹, Michiel van der Heijden², Yohann Loriot³, Johathan Rosenberg⁴, Lawrence Fong⁵, Ira Mellman¹, Daniel S. Chen¹, Marjorie Green¹, Christina Derleth¹, Gregg D. Fine¹, Priti S. Hegde¹, Richard Bourgon¹, Thomas Powles⁶

¹Genentech, Inc., South San Francisco, CA, USA ²Netherlands Cancer Institute, Amsterdam, Netherlands ³Gustave Roussy, Villejuif, France ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA ⁵University of California San Francisco, San Francisco, CA, USA ⁶Barts Experimental Cancer Medicine Centre, London, United Kingdom

Biomarkers | Gene expression | Checkpoint blockade | Clinical trial | Immune monitoring | Tumor microenvironment | Tumor stroma | Tumor infiltrating lymphocytes (TILs)

P14

Comprehensive characterization of solid tumor immune profiles for precision immunotherapy using Immune Report Card

Mary Nesline¹, Jeffrey Conroy¹, Sarabjot Pabla¹, Ji He¹, Blake Burgher¹, Vicent Giamo¹, Jonathan Andreas¹, Paul DePietro¹, Antonios Papanicolau-Sengos¹, Mark Gardner¹, Sean Glenn¹, Carl Morrison¹

¹OmniSeq, Inc., Buffalo, NY, USA

Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Inflammation | Biomarkers | Immune monitoring | Gene expression | Solid tumors | T cell

P15

Overexpression of immunotherapeutic targets in the immune desert phenotype

Sarabjot Pabla¹, Jeffrey Conroy¹, Sean Glenn¹, Ji He¹, Blake Burgher¹, Vincent Giamo¹, Jonathan Andreas¹, Maochun Qin¹, Mark Gardner¹, Antonios Papanicolau-Sengos¹, Mary Nesline¹, Carl Morrison¹

¹OmniSeq, Inc., Buffalo, NY, USA

Tumor microenvironment | Biomarkers | Checkpoint blockade | Immune monitoring | Gene expression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P16

The immune activated phenotype: secondary immunotherapeutic targets in the primary biomarker negative inflamed tumor

Sean Glenn¹, Jeffrey Conroy¹, Sarabjot Pabla¹, Ji He¹, Blake Burgher¹, Vincent Giamo¹, Jonathan Andreas¹, Mark Gardner¹, Antonios Papanicolau-Sengos¹, Mary Nesline¹, Carl Morrison¹

¹OmniSeq, Inc., Buffalo, NY, USA

Tumor microenvironment | Biomarkers | Checkpoint blockade | Immune monitoring | Gene expression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P17

The immune-excluded phenotype beyond colorectal cancer

Carl Morrison¹, Sean Glenn¹, Wiam Bshara², Sarabjot Pabla¹, Blake Burgher¹, Vincent Giamo¹, Jonathan Andreas¹, Mary Nesline¹, Mark Gardner¹, Antonios Papanicolau-Sengos¹, Igor Puzanov², Marc Ernstoff², Jeffrey Conroy¹

¹OmniSeq, Inc., Buffalo, NY, USA ²Roswell Park Cancer Institute, Buffalo, NY, USA

Tumor microenvironment | Biomarkers | Checkpoint blockade | Immune monitoring | Gene expression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P18

Withdrawn

P19

Genomic determinants of response to pembrolizumab in gastric cancer

Razvan Cristescu¹, Diane Levitan¹, Julie Kobie¹, Andrew Albright¹, Ping Qiu¹, Robin Mogg¹, Jared Lunceford¹, Xiao Qiao Liu¹, Xinwei Sher¹, Michael Nebozhyn¹, Gladys Arreaza¹, Wendy Blumenschein¹, Mark Ayers¹, Terrill McClanahan¹, Andrey Loboda¹, David Kaufman¹, Rita Dalal¹, Minori Koshiji¹

¹Merck & Co., Inc., Kenilworth, NJ, USA

Biomarkers | Checkpoint blockade | Gene expression | Solid tumors | Tumor microenvironment

P20

Distinct tumour immune profiles in non-small cell lung cancer (NSCLC) revealed by automated quantitative digital image analyses of immune biomarker densities and spatial relationships

Marie Cumberbatch¹, Elaine Foster², James Clay², Sunita Mistry², Andrew Lawrence², Christopher Womack², David Fairley²

¹Immune Insight Limited, Macclesfield, United Kingdom ²HistologiX Limited, Nottingham, United Kingdom

Immune contexture | Tumor microenvironment | Biomarkers | Immune monitoring | Tumor infiltrating lymphocytes (TILs)

P21

Correlation of inflammatory biomarkers and patient-reported outcomes in patients with urothelial carcinoma treated with durvalumab

Arnold Degboe¹, Srikala Sridhar², Jingsong Zhang³, Pralay Mukhopadhyay¹, Ashok Gupta¹, Lorin Roskos¹, Xiang Guo¹, Terence Friedlander⁴

¹AstraZeneca, Gaithersburg, MD, USA ²Princess Margaret Cancer Centre, Toronto, ON, Canada ³Moffitt Cancer Center, 12902 USF Magnolia Drive, FL, USA ⁴UCSF Medical Center, San Francisco, CA, USA

Biomarkers | Inflammation | Solid tumors | Clinical study

P22

Up-regulation of a T and NK cell gene signature in peripheral blood is associated with mRNA-based immunotherapy in lung and prostate cancer.

Henoch S Hong¹, Madeleine M Hipp¹, Fatma Doener¹, James M Billingsley², Linus Backert³, Oliver Kohlbacher³, Andreas Schröder¹, Ute Klinkhardt¹, Sabine Brutlach¹, Uwe Peukert¹, Ulrike Gnad-Vogt¹, Mariola Fotin-Mleczek¹, Sven D Koch¹

¹CureVac AG, 72076 Tübingen, Germany ²Emory University, Atlanta, GA, USA ³Applied Bioinformatics, University of Tübingen, 72076 Tübingen, Germany

Clinical trial | Immune monitoring | Tumor antigens | NK/NK T cell | T cell | Vaccine | Gene expression | Bioinformatics

P23

Deep molecular and immune-infiltrate stratification of cancer identifies mechanistic subtypes and predicts response to checkpoint inhibition.

Janusz Dutkowski¹, Roy Ronen¹

¹Data4Cure, Inc., La Jolla, CA, USA

Bioinformatics | Checkpoint blockade | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Systems biology | Biomarkers

P24

Systematic Literature Review of PD-L1 Assays, Their Scoring Algorithms and Validation Metrics

Margarita Udall¹, Maria Rizzo², Juliet Kenny², Jim Doherty¹, Eric Faulkner³

¹Pfizer Inc., New York, NY, USA ²Evidera, London, United Kingdom ³Evidera, Morrisville, NC, USA

Biomarkers | Checkpoint blockade | Solid tumors

P25

A Systematic Literature Review (SLR) of the predictive value of programmed death ligand 1 (PD-L1) tests on clinical outcomes

Margarita Udall¹, Jim Doherty¹, Amber Martin², Juliet Kenney³, Eric Faulkner⁴, Pratibha Chander¹, Paul Robbins¹, SueAnn Dahm¹

¹Pfizer Inc., New York, NY, USA ²Evidera, Waltham, MA, USA ³Evidera, London, USA ⁴Evidera, Morrisville, NC, USA

Biomarkers | Checkpoint blockade | Solid tumors

P26

Certain KIR/KIR ligand genotypes influence patient response to immunotherapy in neuroblastoma patient

Amy K. Erbe¹, Wei Wang¹, Lakeesha Carmichael¹, Anna Hoefges¹, KyungMann Kim¹, Wendy B. London², Jacquelyn A. Hank¹, Mitchell B. Diccianni³, Arlene Naranjo⁴, Michael D. Hogarty⁵, Julie R. Park⁶, Alice L. Yu⁷, Paul M. Sondel¹

¹University of Wisconsin-Madison, Madison, WI, USA ²Boston Children’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA ³University of California San Diego, San Diego, CA, USA ⁴University of Florida, Gainesville, FL, USA ⁵Children's Hospital of Philadelphia, Philadelphia, PA, USA ⁶Seattle Children's Hospital, Seattle, WA, USA ⁷University of California San Diego, San Diego, CA, USA

Genetic polymorphism | Pediatric tumors | Biomarkers | Clinical study | Immune toxicity | Targeted therapy | Tumor antigens | Antibody | Clinical trial | NK/NK T cell

P27

Optimized workflow improves the characterization of tumor-infiltrating T cells

Cesar Evaristo¹, Ramona Siemer¹, David Agorku¹, Janina Brauner¹, Olaf Hardt¹, Christian Dose¹, Anne Richter¹

¹Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

Tumor microenvironment | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Immune monitoring | Immune contexture | T cell lineages | Biomarkers

P28

Profiling of T cell responses to tumor-associated antigens in lung cancer patients treated with checkpoint inhibitors

Kyle Ferber¹, Johanna K. Kaufmann¹, Judy Jacques¹, Christine McCoy¹, Michael O'Keeffe¹, Crystal Cabral¹, Yana Ostrovsky¹, Ning Wu¹, Jason Dobston¹, Theresa Zhang¹, Pamela Carroll¹, Jessica Flechtner¹, Wendy Broom¹

¹Genocea Biosciences, Inc., Cambridge, MA, USA

T cell | Antigen presenting cells | Cytokine | Immune suppression | Immune monitoring | Checkpoint blockade | Biomarkers | Tumor antigens | Solid tumors | Vaccine

P29

Incorporating Premixed Staining Cocktail for Improving the Workflow for Whole Blood Immunophenotyping

Iliana Gonzalez¹, Yoshinobu Koguchi¹, William Miller¹, Tanisha Meeuwsen¹, Valerie K. Conrad¹, Ana Howells-Ferreira¹, Tomasz M. Poplonski¹, William Redmond¹

¹Earle A. Chiles Research Institute, Portland, OR, USA

Immune monitoring | Antibody

P30

Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer, including those with brain metastases

Sarah Goldberg¹, Lucia Jilaveanu¹, Harriet Kluger¹, Veronica Chiang¹, Amit Mahajan¹, Bing Xia¹, Matthew Ribeiro¹, Heinrich Roder², Joanna Roder², Carlos Oliveira², Julia Grigorieva², Mirte Muller³, Anna-Larissa Niemeijer⁴, Robert Schouten³, Adrianus de Langen^3,4, Egbert Smit³

¹Yale School of Medicine, New Haven, CT, USA ²Biodesix, Steamboat Springs, CO, USA ³Netherlands Cancer Institute, Amsterdam, Netherlands ⁴VU University Medical Center, Amsterdam, Netherlands

Biomarkers | Checkpoint blockade | Proteomics | Solid tumors | Clinical trial

P31

Proteomic biomarker analysis of metastatic melanoma patients treated with anti-PD-1 checkpoint blockade

Paolo Antonio Ascierto¹, Mariaelena Capone¹, Antonio Maria Grimaldi¹, Domenico Mallardo¹, Ester Simeone¹, Heinrich Roder², Krista Meyer², Senait Asmellash³, Carlos Oliveira², Joanna Roder²

¹Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy ²Biodesix, Steamboat Springs, CO, USA ³Biodesix, Boulder, CO, USA

Biomarkers | Checkpoint blockade | Proteomics | Solid tumors

P32

Differential association of myeloid cell and IFN-γ associated proteins with clinical response to durvalumab treatment in urothelial bladder cancer

Xiang Guo¹, Wendy White¹, Denise Jin², Yanan Zheng², Rajesh Narwal¹, Yu Gu¹, Ashok Gupta¹, Pralay Mukhopadhyay³, Brandon Higgs¹, Tony W. Ho³, Lorin Roskos¹

¹MedImmune, Gaithersburg, MD, USA ²MedImmune, Mountain View, CA, USA ³AstraZeneca, Gaithersburg, MD, USA

Biomarkers | Metabolism | Chemokine | Checkpoint blockade | Solid tumors

P33

The presence of effector immune cells in human CD200 positive tumor samples supports the CD200 immune checkpoint as a novel therapeutic target

Mark Hamilton¹, Rui-Ru Ji², Tony Arulanandam¹, Sharon Barr¹

¹Alexion Pharmaceuticals, Inc., New Haven, CT, USA ²Alexion Pharmaceuticals, Inc., Lexington, MA, USA

Bioinformatics | Pediatric tumors | Biomarkers | Checkpoint blockade | Gene expression | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Proteomics | Tumor microenvironment

P34

Pre-existing anti-therapeutic antibodies against Fc-region determinants shared by rituximab and hu14.18K322A are associated with outcome in a phase I trial of hu14.18K322A

Jacquelyn Hank¹, Jacob Goldberg¹, Fariba Navid², Amy Erbe¹, Victor Santana³, Jacek Gan¹, Fenna de Bie¹, Amal Javaid¹, Anna Hoefges¹, Lakeesha Carmichael¹, Michael Bishop³, Michael Meagher⁴, Stephen Gillies⁵, Janardan Pandey⁶, Paul Sondel¹

¹University of WI-Madison, Madison, WI, USA ²Children’s Hospital Los Angeles, Los Angeles, CA, USA ³St. Jude Children’s Research Hospital, Memphis, TN, USA ⁴3St. Jude Children’s Research Hospital, Memphis, TN, USA ⁵Provenance Biopharmaceuticles, Carlisle, MA, USA ⁶Medical University of South Carolina, Charleston, SC, USA

Biomarkers | Clinical study | Immune monitoring | Targeted therapy | Antibody | Clinical trial | Vaccine

P35

Withdrawn

P36

Computational Tissue Analysis–Based Quantification of Tumor-Infiltrating Leukocytes Using Morphometrics in Immunohistochemistry Stained NSCLC Samples

Elliott Ergon¹, Allison Harney¹, Will Paces¹, Kristin Wilson¹, Karen Ryall¹, Daniel Rudmann¹, Brooke Hirsch¹, Joseph Krueger¹

¹Flagship Biosciences, Westminster, CO, USA

Immune contexture | Inflammation | Tumor microenvironment | Biomarkers | Tumor infiltrating lymphocytes (TILs)

P37

Combining in situvaccination with checkpoint blockade enhances an endogenous anti-tumor B-cell response resulting in tumor-specific humoral memory

Clinton Heinze¹, Claire Baniel¹, Peter Carlson¹, Jacquelyn Hank¹, Raghava Sriramaneni¹, Emily Guy¹, Jasdeep Kler¹, Sara Busche¹, Stephen Gillies², Hans Loibner³, Alan Korman⁴, Alexander Rakhmilevich¹, Paul Sondel¹, Zachary Morris¹

¹Wisconsin Institutes of Medical Research, Madison, WI, USA ²Provenance Biopharmaceuticals, Carlisle, MA, USA ³APEIRON Biologics, Vienna, Austria ⁴Bristol-Myers Squibb, Sunnyvale, CA, USA

B cell | Antibody | Biomarkers | Radiotherapy | Vaccine | Checkpoint blockade

P38

A Strategy to Assess Contributions of Individual Agents in Combination Immunotherapy Trials

Traci Hilton¹, Christopher Paustian¹, Yoshinobu Koguchi², Adi Mehta³, Fridtjof Lund-Johansen⁴, Brian Boulmay, Rui Li, Kyle Happel, Tarsem Moudgil, Sachin Puri, Christopher Dubay, Brenda Fisher, Rogan Rattray, Mary Campbell

¹Ubivac, Portland, OR, USA ²Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA ³Oslo, Norway ⁴Oslo University Hospital Rikshospitalet, Oslo, Norway

B cell | Antibody | Biomarkers | Clinical study | Immune monitoring | Proteomics | Tumor antigens | Vaccine | T cell | Clinical trial

P39

Use of ex vivo Histoculture to identify potential predictive biomarkers for the ICOS agonist antibody, JTX-2011

Heather Hirsch¹, Jason Reeves¹, Tong Zi¹, Amit Deshpande¹, Guang Yang¹, Alexander Needham¹, Jenny Shu¹, Christopher Harvey¹, Sriram Sathyanaryanan¹, Jennifer Michaelson¹, Emma Lees¹, Elizabeth Trehu¹, Debbie Law¹

¹Jounce Therapeutics, Inc., Cambridge, MA, USA

Biomarkers | Checkpoint blockade | Bioinformatics | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Regulatory T cell (Treg)

P40

Deep proteomic and transcriptomic analysis of sorted T cells with a simple, integrated workflow

Kit Fuhrman¹, Douglas Hinerfeld¹, Katherine Drake², Gary Geiss¹

¹Nanostring Technologies, Inc., Seattle, WA, USA ²Cytobank, Inc., Santa Clara, CA, USA

T cell | Gene expression | Targeted therapy | Systems biology | Proteomics | Immune monitoring | Biomarkers | Regulatory T cell (Treg)

P41

IgG antibodies correspond with T cell responses to tumor neoantigens

Tyler Hulett¹, Shawn Jensen¹, Larry David², Ashok Reddy², Phillip Wilmarth², Carmen Ballesteros-Merino¹, Christopher Dubay¹, Michael Afentoulis¹, Bernard Fox¹

¹Earle A. Chiles Research Institute, Portland, OR, USA ²Oregon Health & Science University, Portland, OR, USA

T cell | Antibody | Vaccine | Tumor antigens | Proteomics | Neoantigens | Autoimmunity | Biomarkers | Bioinformatics

P42

The checkpoint inhibitor TTI-621 (SIRPαFc) stimulates innate and adaptive immune responses in patients with hematologic and solid tumor malignancies

Lisa Johnson¹, Stephen Ansell², Robert Chen³, Ian Flinn⁴, Michael Maris⁵, Owen O'Connor⁶, Alexander Lesokhin⁷, John Thompson⁸, Oleg Akilov⁹, Christiane Querfeld³, Matthew Taylor¹⁰, Meghan Irwin¹, Tina Catalano¹, Penka Petrova¹, Eric Sievers¹, Robert Uger¹

¹Trillium Therapeutics Inc., Mississauga, ON, Canada ²Mayo Clinic, Rochester, MN, USA ³City of Hope, Duarte, CA, USA ⁴Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA ⁵Sarah Cannon Research Institute/Colorado Blood Cancer Institute, Denver, CO, USA ⁶Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA ⁷Memorial Sloan Kettering Cancer Center, New York, NY, USA ⁸University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA ⁹University of Pittsburgh, Pittsburgh, PA, USA ¹⁰Oregon Health and Science University, Portland, OR, Canada

Biomarkers | Checkpoint blockade | Immune monitoring | Clinical trial | Cytokine | Monocyte/Macrophage | T cell | Chemokine | Solid tumors

P43

Assessment of Pharmacodynamic Effects of Immuno-Oncology Agents in Cynomolgus Monkeys using High-Content Gene Expression Profiling

Veena Kandaswamy¹, Amelie Forest¹, Thompson Doman², Manisha Brahmachary¹, Krishna Chodavarapu¹, Jason Manro², John Rhoden², Bing Han², Nate Elliott³, Sarah Warren³, Tim Riordan³, Christina Bailey³, Ruslan Novosiadly¹, Michael Kalos¹, Gerald Hall¹

¹Eli Lilly & Company, New York, NY, USA ²Eli Lilly & Company, Indianapolis, IN, USA ³NanoString Technologies, Seattle, WA, USA

Biomarkers | Antibody | Monocyte/Macrophage | T cell | Gene expression

P44

Patient selection strategies and pharmacodynamic assays for CCR4 antagonists

Abood Okal¹, William Ho¹, Brian Wong¹, Paul Kassner¹, Gene Cutler¹

¹FLX Bio Inc., South San Francisco, CA, USA

Bioinformatics | Regulatory T cell (Treg) | Immune suppression | Gene expression | Chemokine | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Biomarkers

P45

The inhibitory checkpoint molecule NKG2A is upregulated on tumor infiltrating NK cells and CD8 T cells in human head and neck tumors

Michael Korrer¹, Young Kim¹

¹Vanderbilt University Medical Center, Nashville, TN, USA

Tumor microenvironment | T cell | NK/NK T cell | Immune suppression | Checkpoint blockade

P46

The impact of anti-PD-1 treatment on the immune cells and their correlation with the circulating tumour cells in patients with non-small cell lung cancer

Eleni-Kyriaki Vetsika¹, Despoina Aggouraki¹, Galaktia Kallergi¹, Zaharoula Lyristi¹, Aristeidis Koukos¹, Despoina Kourougkiaouri¹, Konstantinos Rounis², Vassilis Georgoulias¹, Athanasios Kotsakis²

¹University of Crete, Faculty of Medicine, Heraklion, Greece ²University General Hospital of Heraklion, Crete, Greece, Heraklion, Greece

Biomarkers | Checkpoint blockade | Immune monitoring | Solid tumors

P47

Gene expression analysis of IL-13Rα2 in human adrenocortical carcinoma correlates with poor survival

Abhinav Kumar¹, Ian Bellayr¹, Raj Puri¹

¹Food and Drug Administration, Silver Spring, MD, USA

Bioinformatics | Biomarkers | Gene expression

P48

Different impact of immune cell infiltration and HLA class I expression in lymph node vs. cutaneous/subcutaneous metastases as predictive markers in melanoma patients treated with ipilimumab

Tímea Balatoni¹, Anita Mohos², Eszter Papp¹, Tímea Sebestyén³, Gabriella Liszkay¹, Judit Oláh⁴, Anita Varga⁴, Zsuzsanna Lengyel⁵, Gabriella Emri⁶, Soldano Ferrone⁷, Andrea Ladányi¹

¹National Institute of Oncology, Budapest, Hungary ²Semmelweis University, Budapest, Hungary ³St. John's Hospital, Budapest, Hungary ⁴Albert Szent-Györgyi Medical Center, University of Szeged, Szeged, Hungary ⁵University of Pécs, Pécs, Hungary ⁶Faculty of Medicine, University of Debrecen, Debrecen, Hungary ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Immune contexture | Tumor microenvironment | Biomarkers | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs)

P49

Characterization of immune checkpoint marker expression and infiltrating lymphoid and myeloid immune cells in the tumor microenvironment by RNA in situ hybridization

Annelies Laeremans¹, Na Li¹, Jeffrey Kim¹, Xiao-Jun Ma¹, Emily Park¹

¹Advanced Cell Diagnostics, Newark, CA, USA

Myeloid cells | Regulatory T cell (Treg) | T cell lineages | Tumor microenvironment | Checkpoint blockade | Biomarkers | Immune monitoring | Gene expression | Cytokine | Tumor infiltrating lymphocytes (TILs)

P50

Application of the immunoscore as prognostic biomarkers in patients with epithelial ovarian cancer

Shin-Wha Lee¹, Hee Jung Jung¹, Young-Jae Lee¹, Ha-Young Lee², Yong-Man Kim¹, Young-Tak Kim¹

¹Ulsan University, ASAN Medical Center, Seoul, Republic of Korea ²ASAN Institute for Life Science, Seoul, Republic of Korea

Immune monitoring | Immunoscore | Immune contexture | Biomarkers

P51

FGFR2b expression and baseline immune signature to guide FPA144 development in urothelial cancer

Yeonju Lee¹, Nerissa Mendoza¹, Janine Powers¹, Lee Clark¹, James Hnatyszyn¹, Carmen Ladner¹, Helen Collins¹, Kevin P. Baker¹, Majid Ghoddusi¹

¹Five Prime Therapeutics, Inc., South San Francisco, CA, USA

Tumor microenvironment | Biomarkers | Immune monitoring | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P52

Partially exhausted T lymphocyte directed neoadjuvant immunotherapy in unresectable Stage III melanoma

Lauren Levine¹, Clinton Wu¹, Kelly Mahuron¹, Katy Tsai¹, Alain Algazi¹, Michael Rosenblum¹, Michael Alvarado¹, Adil Daud¹

¹Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

Biomarkers | Checkpoint blockade | Clinical study | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P53

The crosstalk between PD-1, CD137 and OX40 in head and neck cancer

Robert Ferris¹

¹UPCI, Pittsburgh, PA, USA

Antibody | Biomarkers | Costimulation | Coinhibition | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment

P54

Multiplex IHC Immuno-Oncology Panel for standardized profiling of the immune status based on spatial and functional characterization of the tumor microenvironment

Svenja Lippok¹, Florian Leiss¹, Katrin Schneider¹, Tobias Wiestler¹, René Korn¹, Dasa Medrikova¹, Moritz Widmaier¹, Martin Hager¹, Ivan Kanchev¹, Anthony Masci², Gela Sia², Chris Kerfoot², Lisa Dauffenbach², Ralf Huss¹

¹Definiens AG, 80636 Munich, Germany ²Mosaic Laboratories, Lake Forest, CA, USA

Bioinformatics | Tumor microenvironment | Biomarkers | Immunoscore | Immune tolerance | Immune contexture | Inflammation | Checkpoint blockade | Systems biology | Tumor stroma

P55

Non-fucosylated anti-CTLA-4 antibody enhances vaccine-induced T-cell responses in a non-human primate pharmacodynamic vaccine model

John Loffredo¹, Raja Vuyyuru¹, Vanessa Spires¹, Sophie Beyer¹, Maxine Fox¹, Jon Ehrmann¹, Katrina Taylor¹, John Engelhardt¹, Alan Korman¹, Robert Graziano¹

¹Bristol-Myers Squibb, Princeton, NJ, USA

Biomarkers | Checkpoint blockade | Vaccine | T cell | Immune adjuvant | Immune monitoring

P56

Widespread human T cell receptor variable gene polymorphism revealed by long amplicon TCRβ repertoire sequencing: Implications for the prediction and interpretation of immunotherapy outcome

Tim Looney¹, Alex Glavin¹, Sarabjot Pabla², Sean Glenn², Lauren Miller³, Denise Topacio-Hall³, Elizabeth Linch³, Alice Zheng¹, Jeffrey Conroy², Blake Burgher², Carl Morrison², Geoffrey Lowman³, Mark Andersen³, Fiona Hyland¹

¹Thermo Fisher Scientific, South San Francisco, CA, USA ²OmniSeq, Buffalo, NY, USA ³Thermo Fisher Scientific, Carlsbad, CA, USA

Tumor microenvironment | Genetic polymorphism | Adoptive immunotherapy | Autoimmunity | Checkpoint blockade | Immune monitoring | Neoantigens | T cell | Tumor infiltrating lymphocytes (TILs)

P57

Insights into the tumor microenvironment and therapeutic T cell manufacture revealed by long amplicon immune repertoire sequencing

Geoffrey Lowman¹, Tim Looney², Elizabeth Linch¹, Lauren Miller¹, Denise Topacio-Hall¹, Alex Pankov², Alice Zheng², Reidun Hartberg³, Hilde Almåsbak³, Tor Espen Stav-Noraas³, Anette Kullmann³, Fiona Hyland², Mark Andersen¹

¹Thermo Fisher Scientific, Carlsbad, CA, USA ²Thermo Fisher Scientific, South San Francisco, CA, USA ³Thermo Fisher Scientific, Oslo, Norway

Adoptive immunotherapy | T cell lineages | Tumor microenvironment | Tumor antigens | Immune monitoring | Biomarkers | Autoimmunity | CAR T cells | Gene expression | T cell

P58

Public NY-ESO-1 specific TCRs as novel biomarkers for immune monitoring of NY-ESO-1 positive cancer patients

Hailing Lu¹, Seth Pollack², Neeta Somaiah³, Sant Chawla⁴, Patrick Hwu³, Marissa Vignali⁵, Julie Rytlewski⁵, Sacha Gnjatic⁶, Jan ter Meulen¹

¹Immune Design, Seattle, WA, USA ²Fred Hutchinson Cancer Research Center, Seattle, WA, USA ³MD Anderson Cancer Center, Houston, TX, USA ⁴Santa Monica Oncology Center, Santa Monica, CA, USA ⁵Adaptive Biotechnologies, Seattle, WA, USA ⁶Icahn School of Medicine at Mount Sinai, New York, NY, USA

Immune monitoring | Biomarkers | Vaccine | Tumor antigens | Clinical study | Clinical trial

P59

Multi color flow cytometry comparative analysis with DA-Cell(TM) centrifugation-less washing

Xavier Le Guezennec, Ph.D.¹

¹Curiox Biosystems, San Carlos, CA, USA

Biomarkers | Antibody | Systems biology

P60

Comparative Study of Flow Cytometry Analysis between Conventional Centrifuge Method and Centrifuge-less DA-Cell™ Method from the Perspective of Cell Retention

Xavier Le Guezennec¹

¹Curiox Biosystems, San Carlos, CA, USA

Inflammation | Autoimmunity | Antibody | Immune suppression | Immune monitoring | Biomarkers

P61

Cellular and genomic disease signature of peripheral blood mononuclear cells in patients with malignant pleural mesothelioma

Zachary R. Mallon¹, Christophe Poulet¹, Amanda Enstrom¹, Somayeh Honarmand¹, Aimee L. Murphy¹, Raffit Hassan², Dirk G. Brockstedt¹, Chan C. Whiting¹, Nitya Nair¹

¹Aduro Biotech, Inc., Berkeley, CA, USA ²National Cancer Institute, Bethesda, MD, USA

Biomarkers | Immune monitoring | Clinical trial | Gene expression

P62

Circulating T cell Subpopulations Correlate with Immune Inflammatory Signatures at the Tumor Site in Melanoma and Non-Squamous Non-small Cell Lung Cancer

Nataly Manjarrez-Orduño¹, Selena Kansal¹, Laurence Menard¹, Sergey Lezhnin², Can Jiang¹, Paul Kayne¹, Robin Edwards¹, Suzanne Suchard¹, Paul Fischer¹, Bijal Kakrecha¹, Chiang Yu¹, Julie Carman¹, Hongyue Dai², Steven Bernstein¹, Steven Nadler¹

¹Bristol-Myers Squibb, Princeton, NJ, USA ²M2GEN, Tampa, FL, USA

Immune contexture | T cell lineages | Biomarkers | Checkpoint blockade | Immune monitoring | Targeted therapy | T cell | Tumor microenvironment | Clinical study | Gene expression

P63

Measurement of the immune-suppressor nitric oxide within immune cell subsets in patients receiving ipilimumab with a peptide vaccine

Isaac P. Foote¹, Zhihua Chen¹, Y. Ann Chen¹, Adam W. Mailloux¹, Alisha Agrawal¹, Braydon J. Schaible¹, Amod Sarnaik¹, Jeffrey S. Weber², Anders E. Berglund¹, James J. Mulé¹, Joseph Markowitz¹

¹Moffitt Cancer Center, Tampa, FL, USA ²NYU, New York, NY, USA

Bioinformatics | Checkpoint blockade | Biomarkers | Immune monitoring

P64

Analytical Validation of Digital Spatial Profiling - a novel approach for multiplexed characterization of protein distribution and abundance in FFPE tissue sections

Kristi Barker¹, Heather Metz¹, Chris Merritt¹, Lucas Dennis¹, Philippa Webster¹, Joseph Beechem¹

¹NanoString Technologies, Inc., Seattle, WA, USA

Tumor microenvironment | Tumor stroma | Tumor antigens | Tumor infiltrating lymphocytes (TILs) | T cell | Antibody | Solid tumors | Biomarkers

P65

Spatially-resolved, multiplexed digital characterization of protein abundance in FFPE tissue sections: application in preclinical mouse models

Yan Liang¹, Alison VanSchoiack¹, JingJing Gong¹, Chris Merritt¹, Dwayne Dunaway¹, Jaemyeong Jung¹, Isaac Sprague¹, Sarah Warren¹, Joseph Beechem¹

¹NanoString Technologies Inc., Seattle, WA, USA

Regulatory T cell (Treg) | T cell lineages | Tumor microenvironment | Biomarkers | Tumor antigens | Tumor stroma | Antibody | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P66

Digital spatial profiling platform allows both spatially-resolved, multiplexed measurement of solid tumor and immune-associated protein distribution and abundance using a single FFPE tissue section

Youngmi Kim¹, Chris Merritt¹, Giang Ong¹, Kristi Barker¹, Jaemyeong Jung¹, Isaac Sprague¹, Yan Liang¹, Sarah Warren¹, Philippa Webster¹, Dwayne Dunaway¹, Joseph Beechem¹

¹NanoString Technologies Inc., Seattle, WA, USA

Regulatory T cell (Treg) | T cell lineages | Tumor microenvironment | Antibody | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor stroma | Tumor antigens | Biomarkers

P67

Standardization of tumor infiltrating lymphocytes isolation for flow cytometric analysis

William Miller¹, Yoshinobu Koguchi¹, William Redmond¹

¹Earle A. Chiles Research Institute, Portland, OR, USA

Tumor infiltrating lymphocytes (TILs) | Immune monitoring

P68

Immunogenomic evolution and atypical response to atezolizumab in a patient with metastatic triple-negative breast cancer (mTNBC)

Luciana Molinero¹, Yijin Li¹, Ching-Wei Chang¹, Sophia Maund¹, Maureen Berg², Jeanne Harrison², Marcella Fassò¹, Carol O’Hear¹, Priti S. Hegde¹, Leisha A. Emens³

¹Genentech, Inc., South San Francisco, CA, USA ²Johns Hopkins School of Medicine, Baltimore, MD, USA ³Johns Hopkins University School of Medicine, Baltimore, MD, USA

Biomarkers | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Tumor stroma | Tumor microenvironment | Immune monitoring | Clinical study | Gene expression

P69

A pan-cancer diagnostic, prognostic and targetable biomarker pipeline defining the failed immune-response

Anne Monette^1,2, Antigoni Morou^1,2, Louise Rousseau², Jean-Baptiste Lattouf¹, Daniel Kaufmann¹, Igor Jurisica³, Rejean Lapointe^1,2

¹University of Montreal, Montreal, QC, Canada ²CRCHUM, Montreal, QC, Canada ³University of Toronto / 7Princess Margaret Cancer Centre and Techna, Toronto, ON, Canada

T cell | B cell | Bioinformatics | Biomarkers | Systems biology | Gene expression | Immune tolerance | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Immune monitoring

P70

Halioseek™, a dual CD8 and PD-L1 IVD assay to improve NSCLC patients stratification

Florence Monville¹, Emmanuel Prestat¹, Laurent Vanhille¹, Julien Adam², Sergiu Coslet³, Caroline Laugé¹, Caroline Davin¹, Merle Sophie Losch¹, Luciana Batista¹, Jacques Fieschi¹

¹HalioDx, Marseille, France ²Gustave Roussy Cancer Campus, Villejuif, France ³MImAbs, Marseille, France

Immune contexture | Tumor microenvironment | Biomarkers | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Solid tumors | T cell | Antibody

P71

Peptide-induced whole blood gene expression analysis for peptide-specific T-cell response

Taku Murakami¹, Keiji Dohi², Kenji Kuwabara², Mieko Ogura¹, Masato Mitsuhashi¹

¹Hitachi Chemical Co. America, Ltd., Irvine, CA, USA ²Shionogi & Co., Ltd., Osaka, Japan

Biomarkers | T cell | Vaccine | Gene expression

P72

Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat (ENT) and pembrolizumab (PEMBRO)

Melissa L. Johnson¹, Dmitry Gabrilovich², Fang Wang², Rene Gonzalez³, Mateusz Opyrchal⁴, David Tamang⁵, Emmett Schmidt⁶, Michael L. Meyers⁷, Peter Ordentlich⁵, Sanjiv S. Agarwala⁸

¹Sarah Cannon Research Institute, Nashville, TN, USA ²The Wistar Institute, Philadelphia, PA, USA ³University of Colorado Comprehensive Cancer Center, Aurora, CO, USA ⁴Roswell Park Cancer Institute, Buffalo, NY, USA ⁵Syndax Pharmaceuticals, Inc., Waltham, MA, USA ⁶Merck & Co., Inc., Kenilworth, NJ, USA ⁷Syndax Pharmaceuticals, Inc., New York, NY, USA ⁸St. Luke’s Cancer Center and University Health Network, Easton, PA, USA

Immune monitoring | Immune suppression | Checkpoint blockade | Clinical study | Clinical trial | Inflammation | Myeloid cells | Tumor microenvironment | Biomarkers | MDSC

P73

First-in-human neoadjuvant study of the immunogenomic impact of the oral IDO inhibitor epacadostat (INCB024360) on the tumor microenvironment of advanced ovarian cancer.

Junko Matsuzaki¹, Amit Lugade¹, Wiam Bshara¹, Katherine Collins¹, Sarah Warren², Patrick Danaher², Lucas Dennis², Antonios Papanicolau-Sengos¹, Leonard D’Amico³, Nirasha Ramchurren³, Angela Omilian¹, Kevin Eng¹, Sebastiano Battaglia¹, Robert Newton⁴, Peggy Scherle⁴, Lance Leopold⁴, Steven Fling³, Richard Shine³, Martin Cheever³, Melissa Geller⁵, Kunle Odunsi¹

¹Roswell Park Cancer Institute, Buffalo, NY, USA ²Nanostring, Seattle, WA, USA ³CITN, Seattle, WA, USA ⁴Incyte Corporation, Wilmington, DE, USA ⁵University of Minnesota, Minneapolis, MN, USA

Biomarkers | Immune monitoring | Tumor microenvironment | Immune suppression | Gene expression

P74

Increasing the levels of anti-beta glucan antibodies by administration of intravenous immunoglobulin (IVIG) induces immunopharmacodynamic (IPD) responses of a novel immunotherapeutic Imprime PGG

Nadine Ottoson¹, Keith Gorden¹, Blaine Rathmann¹, Xiaohong Qiu¹, Ben Harrison¹, Michele Gargano¹, Nandita Bose¹, Gautam Jha², Arkadiusz Dudek³

¹Biothera Pharmaceuticals, Eagan, MN, USA ²The University of Minnesota, Minneapolis, MN, USA ³HealthPartners Institute, St. Paul, MN, USA

Biomarkers | Clinical study | Monocyte/Macrophage | Immune monitoring

P75

iSEND Is an Algorithmic Model Specific for Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1 / PD-L1 Inhibitors

Wungki Park¹, Vaia Florou¹, Sandra Algaze¹, Diana Saravia¹, Deukwoo Kwon^1,2, Gilberto Lopes¹

¹University of Miami Miller School of Medicine, Miami, FL, USA ²Sylvester Comprehensive Cancer Center, Miami, FL, USA

Biomarkers | Checkpoint blockade | Myeloid cells | Clinical study

P76

Usefulness of automated multidimensional flow cytometry analyses for monitoring the status of T and APC compartments in breast cancer patients under neoadjuvant chemotherapy

David Bernal-Estévez¹, Carlos Parra-López²

¹Fundación Salud de los Andes, Bogota, Colombia ²Universidad Nacional de Colombia, Bogota, Colombia

Antigen presenting cells | Bioinformatics | Chemotherapy | Dendritic cell | Immune contexture | Biomarkers | Immune monitoring | T cell

P77

The Novel IL-2 Cytokine Immune Agonist NKTR-214 Harnesses the Adaptive and Innate Immune System for the Treatment of Solid Cancers

Salah Eddine Bentebibel¹, Chantale Bernatchez¹, Cara Haymaker¹, Michael Hurwitz², Patrick Hwu¹, Mario Sznol², Nizar Tannir¹, Sandra Aung³, Michael Imperiale³, Mary Tagliaferri³, Christie Fanton³, Ernesto Iacucci³, Jonathan Zalevsky³, Ute Hoch³, Adi Diab¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA ²Yale School of Medicine, New Haven, CT, USA ³Nektar Therapeutics, San Francisco, CA, USA

Solid tumors | Tumor infiltrating lymphocytes (TILs) | Cytokine | Regulatory T cell (Treg) | Biomarkers | Tumor microenvironment | Gene expression | Clinical trial | Immune monitoring | T cell

P78

Immune, molecular and T cell repertoire landscape of 235 resected non-small cell lung cancers, paired normal lung and peripheral blood mononuclear cells

Alexandre Reuben¹, Rachel Gittelman², Jiexin Zhang¹, Runzhe Chen¹, Kelly Quek¹, Luis Vence¹, Irina Fernandez-Cubelo¹, Carmen Behrens¹, Jianjun Gao¹, Erik Yusko³, Ryan Emerson³, Sharon Benzeno³, Marissa Vignali³, Christopher Tipton⁴, Ali Jalali¹, Won-Chul Lee¹, Jun Li¹, Xifeng Wu¹, Yuanqing Ye¹, Agda Eterovic¹, Latasha Little¹, Curtis Gumbs¹, Vancheswaran Goplakarishnan¹, Chantale Bernatchez¹, Cara Haymaker¹, Marie-Andrée Forget¹, Lorenzo Federico¹, Tina Cascone¹, Harlan Robins⁵, Emily Roarty¹, Jaime Rodriguez¹, Edwin Parra¹, Jennifer Wargo¹, James Allison¹, Padmanee Sharma¹, Jianhua Zhang¹, Jack Lee¹, Boris Sepesi¹, Stephen Swisher¹, Don Gibbons¹, John Heymach¹, Andy Futreal¹, Ignacio Wistuba⁶, Jianjun Zhang⁶

¹MD Anderson Cancer Center, Houston, TX, USA ²Adaptive Biotechnologies, Seattle, WA, USA ³Adaptive Technologies, Seattle, WA, USA ⁴Emory University School of Medicine, Atlanta, GA, USA ⁵MD Anderson Cancer Center, Seattle, WA, USA ⁶MD Anderson, Houston, TX, USA

Adoptive immunotherapy | Immune contexture | Tumor infiltrating lymphocytes (TILs) | T cell | Immune monitoring

P79

T-cell inflamed gene expression profile (GEP) analysis of pembrolizumab- and ipilimumab-treated patients with advanced melanoma in the multicenter, randomized, open-label phase 3 KEYNOTE-006 study

Antoni Ribas¹, Caroline Robert², Jacob Schachter³, Georgina Long⁴, Ana Arance⁵, Jean-Jacques Grob⁶, Matteo Carlino⁷, James Larkin⁸, Andrea Webber⁹, Robin Mogg⁹, Mark Ayers⁹, Jared Lunceford⁹, Fang Liu⁹, Michael Nebozhyn⁹, Andrew Albright⁹, Wendy Blumenschein⁹, Clemens Krepler⁹, David Kaufman⁹, Nageatte Ibrahim⁹, Adil Daud¹⁰

¹University of California, Los Angeles, Los Angeles, CA, USA ²Gustave Roussy and Paris-Sud University, Villejuif, France ³Ella Lemelbaum Institute for Melanoma, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel ⁴Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney, Australia ⁵Hospital Clinic de Barcelona, Barcelona, Spain ⁶Aix Marseille University, Hôpital de la Timone, Marseille, France ⁷Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Blacktown, Australia ⁸Royal Marsden Hospital, London, United Kingdom ⁹Merck & Co., Inc., Kenilworth, NJ, USA ¹⁰University of California, San Francisco, San Francisco, CA, USA

Antibody | Biomarkers | Checkpoint blockade | Clinical trial | Clinical study | Gene expression | Solid tumors | Targeted therapy | T cell | Tumor microenvironment

P80

Testing Systems Immune Monitoring by Mass Cytometry for Clinical Correlative Research

Caroline Roe¹, Allison Greenplate¹, Jonathan Irish¹

¹Vanderbilt University, Nashville, TN, USA

Systems biology | T cell | Immune monitoring | Biomarkers | Checkpoint blockade | Targeted therapy

P81

The immunomodulatory effects of cancer therapy on IFN-gamma responses in the periphery

Laura Rosa Brunet¹, James Crooks², Andrew MacDonald², Samuel LaBrie³, Dominic Eisinger³

¹Immodulon Therapeutics Ltd, Uxbridge, United Kingdom ²Manchester University, Manchester, United Kingdom ³Myriad RBM, Austin, TX, USA

Biomarkers | Immune monitoring | Immune adjuvant | Dendritic cell | T cell

P82

Potential biomarkers in mRCC patients treated with nivolumab

Maria Sayapina¹, Dmitry Nosov², Nikita Savelov³, Nina Lyubimova¹, Yuriy Timofeev¹

¹N.N. Blokhin Russian Oncology Research Center, Moscow, Russian Federation ²The Central Clinical Hospital for Presidential Affairs, Moscow, Russian Federation ³The Moscow City Oncology Hospital No. 62, Istra, Russian Federation

Biomarkers | Checkpoint blockade | Solid tumors

P83

Characterizing Cancers by Prevalence on the PD-L1/CD8 Axis

Guenter Schmidt¹, Keith Steele², Armin Meier¹, Thomas Herz¹, Tze Heng Tan¹, Brandon Higgs², Sonja Althammer¹, Ralf Huss¹

¹Definiens AG, Munich, Germany ²MedImmune LLC, Gaithersburg, MD, USA

Immune contexture | Bioinformatics | Immunoscore | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Biomarkers | Tumor microenvironment | Solid tumors

P84

Relevance of the microenvironment and MHC class I mediated immune escape mechanisms of tumors for anti-tumoral immune responses

Barbara Seliger¹

¹Institute of Medical Immunology, Halle, Germany

Tumor microenvironment | Immune contexture | Tumor evasion | Immune monitoring | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immune suppression | Immunoscore | T cell | Biomarkers

P85

HAAH and MMP9 are Complementary Cancer Biomarkers and Together Potentially Enhanced Predictors of Metastasis

Mark Semenuk¹, Eleanor Ghanbari¹, Anokhi Cifuentes¹, Anjali Kalra¹, Michael Lebowitz¹, Hossein Ghanbari¹

¹Panacea Pharmaceuticals Inc, Gaithersburg, MD, USA

Biomarkers | Tumor antigens | Tumor microenvironment | Tumor evasion

P86

Altered immune cell repertoire and activity after checkpoint blockade immunotherapy with nivolumab in renal cell carcinoma

Michael Staehler¹, Chiara Massa², Annabel Spek¹, Daniel Bethmann², Jurgen Bukur², Anja Mueller², Claudia Wickenhauser², Bernard A. Fox³, Barbara Seliger²

¹Ludwig Maximilian University, Munich, Germany ²Martin Luther University, Halle, Germany ³Robert W. Franz Cancer Research Center, Portland, OR, USA

Biomarkers | Checkpoint blockade | Solid tumors

P87

Results of epigenetic-based quantitative PCR assisted immune cell counting analysis in bavituximab SUNRISE trial subgroup

Nikoletta L. Kallinteris¹, Thomas O. Kleen², Min Tang¹, Shen Yin¹, Tobi Guennel³, Jennifer Lai¹, Victor Nowakowski², Steven Olek², Steve King¹, Joseph S. Shan¹

¹Peregrine Pharmaceuticals, Tustin, CA, USA ²Epiontis GmbH, Berlin, Germany ³Precision Medicine, Frederick, MD, USA

Biomarkers | Clinical trial | Antibody | Monocyte/Macrophage | MDSC | Checkpoint blockade | Immune suppression | T cell | NK/NK T cell | Regulatory T cell (Treg)

P88

CD96, a new candidate for checkpoint blockade in human hepatocellular carcinoma

Zhigang Tian¹, Cheng Sun¹

¹Institute of Immunology, The Key Laboratory of Innate Immunity and Chronic Disease (Chinese Academy of Medical Science), School of Life Sciences and Medical Center, University of Science & Technology of China, hefei, China

Checkpoint blockade | Immune tolerance | NK/NK T cell | Tumor infiltrating lymphocytes (TILs)

P89

Plasma-derived exosomes carrying CTLA-4, PD-1 and PD-L1 in head and neck squamous cell carcinoma patients treated with immunotherapy is associated with disease outcome

Marie-Nicole Theodoraki¹, William E. Gooding², Robert L. Ferris¹, Theresa L. Whiteside¹

¹University of Pittsburgh, Pittsburgh, PA, USA ²Hillman Cancer Center, Pittsburgh, PA, USA

Immune monitoring | Clinical trial | Checkpoint blockade

P90

RNA-based immune gene set signatures demonstrate immune modulation by RXDX-106, a novel TAM (TYRO3, AXL, MER) family small molecule kinase inhibitor

Elizabeth Tindall¹, Heather Ely¹, Yumi Yokoyama¹, Colin Walsh¹, Erin Lew¹, Amy Diliberto¹, Robin Nevarez¹, Jack Lee¹, Ian Silverman¹, Joanne Oh¹, Gary Li¹, Amanda Albert¹, Jason Christiansen¹, Robert Shoemaker¹

¹Ignyta, San Diego, CA, USA

Bioinformatics | Tumor microenvironment | Biomarkers | Immunoscore | Gene expression | Immune monitoring

P91

A harmonized evaluation system for expression of HLA class I antigens in formalin-fixed paraffin embedded cancer tissues

Toshihiko Torigoe¹, Nobuyoshi Hiraoka², Naoya Nakamura³, Eri Atsuyama⁴, Shingo Toji⁵, Yuji Heike⁴

¹Sapporo Medical University School of Medicine, Sapporo, Japan ²National Cancer Center Hospital, Tokyo, Japan ³Tokai University School of Medicine, Isehara, Japan ⁴St Luke’s International University, Tokyo, Japan ⁵Medical Biological Laboratories Co., Ltd., Ina, Japan

Immune tolerance | Tumor microenvironment | Biomarkers | Immune monitoring | Tumor antigens | Immunoscore | Solid tumors | Tumor evasion

P92

Early Biomarker Correlates of Severe Neurologic Events and Cytokine Release Syndrome in ZUMA-1, A Multicenter Trial Evaluating Axicabtagene Ciloleucel in Refractory Agressive Non-Hodgkin Lymphoma

Frederick Locke¹, Marika Sherman², John Rossi², Allen Xue², Michelle Mojadidi², Sattva Neelapu³, Armin Ghobadi⁴, Lazaros Lekakis⁵, David Miklos⁶, Caron Jacobson⁷, Olalekan Oluwole⁸, Tanya Siddiqi⁹, Yi Lin¹⁰, Patrick Reagan¹¹, William Go², Jeff Wiezorek², Adrian Bot²

¹Moffitt Cancer Center, Tampa, FL, USA ²Kite Pharma, Santa Monica, CA, USA ³The University of Texas MD Anderson Cancer Center, Houston, TX, USA ⁴Washington University School of Medicine, Saint Louis, MO, USA ⁵University of Miami Health System, Sylvester Comprehensive Care Center, Miami, FL, USA ⁶Stanford University School of Medicine, Stanford, CA, USA ⁷Dana-Farber Cancer Institute, Boston, MA, USA ⁸Vanderbilt-Ingram Cancer Center, Nashville, TN, USA ⁹City of Hope National Medical Center, Duarte, CA, USA ¹⁰Mayo Clinic, Rochester, MN, USA ¹¹University of Rochester Medical Center,, Rochester, MN, USA

Antigen presenting cells | Biomarkers | CAR T cells | Leukemia/Lymphoma | T cell | Adoptive immunotherapy | Immune contexture | Inflammation

P93

Small molecule binders of Ly6K inhibit tumorigenic growth and induce immunity via TGFb/Stat1 and PDL1 pathway

Megha Kumar¹, Jinya Chen¹, Idalia Cruz¹, Purushottam Tiwari¹, Aykut Uren¹, Maksymilian Chruszcz², Michael B. Atkins¹, Louis M. Weiner¹, Geeta Upadhyay¹

¹Lombardi Comprehensive Cancer Center, Georgetown University Medical center, Washington, DC, USA ²Lombardi Comprehensive Cancer Center, Georgetown University Medical center, Columbia, SC, USA

Tumor microenvironment | Stem cell/cancer-initiating cell | Biomarkers | Immune monitoring | Carcinogenesis | Solid tumors | Checkpoint blockade

P94

The RareCyte® platform for identifying rare antigen-specific circulating CD4 and CD8 T cells in Merkel cell carcinoma

Lance U'Ren¹, Natalie Vandeven², Erika Hayes³, Jennifer Chow¹, Jackie Stilwell¹, Paul Nghiem², Eric Kaldjian¹

¹RareCyte Inc., Seattle, WA, USA ²University of Washington, Seattle, WA, USA ³Benaroya Research Institute, Seattle, WA, USA

Biomarkers | Checkpoint blockade | Immune monitoring | T cell

P95

Development and application of a 6-channel immunofluorescence assay for investigating PDL1 and IFR1 expression on circulating tumor cells

Lance U'Ren¹, Daniel Campton¹, Jackie Stilwell¹, Eric Kaldjian¹

¹RareCyte Inc, Seattle, WA, USA

Biomarkers | Checkpoint blockade | Solid tumors

P96

Tumor mutation burden, microsatellite instability and chromosomal instability analysis using low pass whole genome sequencing of single circulating tumor cell

Angel Rodriguez¹, Jerry Lee¹, Ramsay Sutton¹, Rhett Jiles¹, Yipeng Wang¹, Mark Landers¹, Ryan Dittamore¹

¹Epic Sciences, San Diego, CA, USA

Biomarkers | Bioinformatics | Antigen presenting cells | Genetic polymorphism | Stem cell/cancer-initiating cell

P97

Simultaneous Characterization of Rare Immune cell Subpopulations and PD-L1 expressing CTCs in peripheral blood of cancer patients

Adam Jendrisak¹, Angel Rodriguez¹, Jiyun Byun¹, Ryon Graf¹, Yipeng Wang¹, Mark Landers¹, Ryan Dittamore¹

¹Epic Sciences, San Diego, CA, USA

Immune tolerance | Immune suppression | Stem cell/cancer-initiating cell | Immune monitoring | Biomarkers | NK/NK T cell

P98

Immunological profiling of baseline and resected biopsies from locally/regionally advanced/recurrent melanoma treated with neoadjuvant combination ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2B

Sarah Warren¹, Priyanka Vallabhaneni², Jack El-Sawada², Andrew White¹, Xing Ren¹, Alessandra Cesano¹, Joseph Beechem¹, Ahmad Tarhini²

¹NanoString Technologies, Inc., Seattle, WA, USA ²Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Immune contexture | Immune tolerance | Biomarkers | Checkpoint blockade | Clinical study | Immune monitoring

P99

Biomarker analysis from the OpACIN trial (Neo-/adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma)

Lisette (EA) Rozeman¹, Lorenzo Franchi¹, Thomas Kuilman¹, Oscar Krijgsman², Alexander (ACJ) van Akkooi¹, Pia Kvistborg¹, Hans van Thienen¹, Bauke Stegenga³, Dana Cullen³, Brian Lamon³, John (JBAG) Haanen¹, Alessandra Cesano⁴, Sarah Warren⁴, Annegien Broeks¹, Ton Schumacher¹, Christian Blank¹

¹Netherlands Cancer Institute, Amsterdam, Netherlands ²o.krijgsman@nki.nl, Netherlands, Netherlands ³Bristol-Myers Squibb, Lawrence Township, NJ, USA ⁴NanoString Technologies, Seattle, WA, USA

Immune contexture | Immune tolerance | Tumor microenvironment | Biomarkers | Checkpoint blockade | Clinical study | Immune monitoring | Tumor evasion

P100

Pretreatment gene expression correlation with clinical response to pembrolizumab or nivolumab in metastatic melanoma

Sarah Warren¹, Patrick Danaher¹, Tobias Schatton²

¹NanoString Technologies, Seattle, WA, USA ²Brigham-Women's Hospital, Boston, MA, USA

Bioinformatics | Immune contexture | Immune tolerance | Biomarkers | Immune suppression

P101

Multiplex Biomarker Detection in FFPE Tumour Samples

Mike Millar¹, Louise Welch¹, Dawn Lyster¹, Mariana Beltran¹, Sevi Giakoumelou¹

¹Aquila BioMedical, Edinburgh, United Kingdom

Tumor microenvironment | Immune monitoring | Biomarkers | Immune contexture | Antigen presenting cells | Myeloid cells | Tumor antigens | B cell | T cell

P102

Mining the periphery for tumor-relevant B and T cells

Katherine L. Williams¹, Lukas Pfannenstiel², Eldar Giladi¹, Yvonne Leung¹, Xiaobin Tang¹, Shuwei Jiang¹, Dongkyoon Kim¹, Kevin Williamson¹, Sean M. Carroll¹, Ngan Nguyen¹, Gregg Espiritu Santo¹, Sini Reponen¹, Xiaomu Chen¹, Norman M. Greenberg¹, Daniel Emerling¹, Wayne Volkmuth¹, Brian Gastman², Guy Cavet¹

¹Atreca, Inc., Redwood City, CA, USA ²Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA

T cell lineages | Immune monitoring | Biomarkers | Antibody | B cell | T cell | Tumor infiltrating lymphocytes (TILs)

P103

Tumor infiltrating lymphocyte (TIL) percentage as a prognostic biomarker for overall and relapse free survival in Hu14.18-IL2 treated resectable recurrent stage 3 or 4 melanoma patients

Richard Yang¹, Mark Albertini², Jacquelyn Hank², Hans Loibner³, Stephen Gillies⁴, Paul Sondel², Erik Ranheim²

¹University of Wisconsin - Madison Hospitals and Clinics, Madison, WI, USA ²University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA ³Apeiron Biologics, Vienna, Austria ⁴Provenance Biopharmaceuticals, Carlisle, MA, USA

Tumor infiltrating lymphocytes (TILs) | Immune monitoring | Clinical trial | Biomarkers | Tumor microenvironment | Targeted therapy | Surgery | Immune contexture | Clinical study | Antibody

P104

A study of PD-L1 diagnostic assay concordance in urothelial carcinoma

Magdalena Zajac¹, Marietta Scott¹, Marianne Ratcliffe², Alan Sharpe¹, Paul W Scorer¹, Craig Barker¹, Hytham Al-Masri³, Marlon Rebelatto⁴, Jill Walker¹

¹AstraZeneca, Cambridge, United Kingdom ²AstraZeneca, Macclesfield, United Kingdom ³Hematogenix, Tinley Park, IL, USA ⁴Medimmune, Gaithersburg, MD, USA

Biomarkers | Targeted therapy

P105

Infino: Bayesian inference to distinguish immune cell expression phenotypes, estimate immune infiltration into tumor microenvironment, and investigate exhausted T cell phenotype

Maxim Zaslavsky¹, Jacqueline Buros Novik¹, Eliza Chang¹, Alexander Huang², Josephine Giles², Robert Orlowski², E. John Wherry², Jeffrey Hammerbacher¹

¹Icahn School of Medicine at Mount Sinai, New York, NY, USA ²Perelman School of Medicine, Philadelphia, PA, USA

Tumor microenvironment | Biomarkers | Gene expression | Immune contexture | Immunoscore | Tumor infiltrating lymphocytes (TILs)

P106

Bioinformatic analysis of the tumor immune landscape to prioritize combinations with antibody-drug conjugates (ADCs)

Xiaoling Zhang¹, Song Wu¹, Brandon W. Higgs¹, Koustubh Ranade¹

¹MedImmune, Gaithersburg, MD, USA

Adoptive immunotherapy | Bioinformatics | Chemotherapy | Tumor microenvironment | Checkpoint blockade | Clinical study | Antibody | Gene expression | Solid tumors